• Users Online: 226
  • Print this page
  • Email this page
Year : 2021  |  Volume : 4  |  Issue : 2  |  Page : 335-346

Olaparib: A narrative drug review

1 Department of Medical Oncology, Hemat-Oncology and Bone Marrow Transplant, Paras Hospital, Gurugram, Haryana, India
2 Department of Medical Oncology, Dr. B.R.A. IRCH, AIIMS, New Delhi, India

Correspondence Address:
Vibhor Sharma
Department of Medical Oncology, Paras Hospital, C-1, Sushant Lok 1, Sector 43, Gurugram - 122 002, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/CRST.CRST_107_21

Get Permissions

Olaparib is an oral anticancer drug that inhibits the poly adenosine diphosphate-ribose polymerase protein (PARP). It is approved for use in advanced ovarian, breast, pancreatic, and prostate cancers. For this review, we comprehensively searched the PubMed database and Google for randomized trials and meta-analyses using the keywords “breast cancer,” “pancreatic cancer,” “ovarian cancer,” “prostate cancer,” and “olaparib.” A total of 78 randomized studies, meta-analyses, and other studies were identified, of which 70 were finally included. In this review, we have attempted to elucidate the history, pharmacokinetics, pharmacodynamics, adverse event profile, and special scenarios nvolving the use of olaparib. In addition, we have briefly reviewed the existing literature for its use in ovarian, pancreatic, breast, and prostate cancers.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal